Good morning, Thomas Morgan here with Thursday's AM NewsMail.

Patients of a life-saving cancer and endometriosis drug say they are scared for their future after the medication was pulled from shelves by a major pharmaceutical manufacturer. It comes at a time when US pharma giants are increasingly showing their frustration with what they say is Australia's "egregious and discriminatory" PBS.

But first, how much of a threat does AI pose? And what opportunities does it present? That's where we start this morning, with a series of reports on how artificial intelligence is impacting governments, the public and the job market.

And we also have a special report from inside Alice Springs town camps, where the death of five-year-old Kumanjayi Little Baby has attracted scrutiny to the "shocking" state of housing.

What's the story? One of the main players in the AI field is so alarmed by its own creation, it isn't releasing it publicly. But now the Australian government and several private companies based here have been granted access to Anthropic's Mythos artificial intelligence model.

What is Mythos? Put simply, it is a powerful AI model that can identify flaws in software and networks. Anthropic, the company behind Claude AI and that is responsible for developing Mythos, says the tech would pose a threat to global security if it fell into the wrong hands.

How is Canberra reacting? The government is in "no comment" mode over Anthropic's announcement. Meanwhile, one independent MP is calling on the government to step up its response to AI amid concerns Australia is not preparing fast enough for the opportunities or risks.

AI analysis: So how are Australians responding to all this news about AI? As our artificial intelligence reporter Cam Wilson writes, Big Tech and the government are now grappling with deep voter distrust towards the technology just as it triggers a major data centre infrastructure boom.

But it isn't all doom and gloom: AI might be tightening the job market in places, but a new report suggests it could also be "shifting" the workforce and helping create more roles elsewhere. As Deloitte marks 2026 as the "year of AI", it says the real winners from the technology will be companies that combine the strengths of both humans and machines.

• 'Cruel' decision: A life-saving breast cancer and endometriosis drug has been pulled from the PBS by AstraZeneca, in a move that is being described as "soul-destroying" by one woman fighting stage-four metastatic breast cancer. The health department says AstraZeneca's decision was made for "commercial reasons".
• Once-in-a-decade opportunity: The diving industry is backing calls for an expansion of no-fish, no-drill zones across the nation's oceans as a review into our marine parks looms. That could be a boon for tourists and operators, but the fishing sector is warning any expansion of sanctuary zones could leave some regional jobs reeling.
• Varroa mite: Queensland's honey bee population is being devastated by the invasive mite, just a year after it was first detected in the state. It's estimated 90 per cent of south-east Queensland's honey bee colonies have collapsed and bee keepers are paying thousands to fend off the parasite. 
• Betting expansion: Anti-gambling advocates say they are alarmed by Sportsbet's parent company's decision to launch a rewards club. The loosely regulated giveaway sector, which operates under "trade promotion" laws, has been experiencing a boom in recent years. 

• Under the radar: Changes to the delivery of AUKUS were announced over the weekend, but it appears the tweaks may have been in train for quite some time, according to Senate estimates. Adjustments to the pact mean Australia will buy three second-hand submarines, rather than two second-hand and one new.
• Relief and fear: Those who recently entered the property market say they are worried about the risk of falling into negative equity as house prices slide on the back of interest rates and the budget changes. But for those seeking to buy their first home, cooling property prices could present a huge opportunity.
• And on the broader economy: The slowdown could be just beginning, according to economists. The Iran war is weighing on optimism and inflating fears of a recession, but that's not tempering expectations that the RBA may keep raising interest rates.
• 'A little perturbed': That's how Donald Trump is characterising his phone call with Benjamin Netanyahu that has been subject to plenty of media headlines in recent days. US media reports the US president was furious and at one point told the Israeli leader that he was "f***ing crazy".

— That's Robin Japanangka Granites, the grandfather of Kumanjayi Little Baby whose death last month caused nationwide heartache and shone a spotlight on the conditions many Indigenous people face in Alice Springs's 16 town camps. 

Our NT reporter Matt Garrick has visited the Old Timers town camp where the five-year-old girl was abducted from, hearing from residents including Robin who are appalled at living conditions in these small and oft-forgotten communities. And he was granted a rare interview with the head of the council responsible for providing services and maintenance to homes around the Red Centre, in this exclusive story for 7.30.

WATCH: You can also view Matt's report from Alice Springs in full on last night's episode of 7.30. (▶️9m25s)

Finally this morning, before he won four Oscars at the 2025 Academy Awards for his film Anora, Sean Baker was growing up being the "'AV guy' at high school" and watching summer blockbusters by Spielberg and Lucas.

But no more. With that Hollywood recognition comes an enormous step change in terms of recognition and budgets.

Nevertheless, Baker, who is bringing his filmmaking tips to Sydney as part of the Vivid Festival, has sat down with ABC Arts's Stephen A Russel to explain why his new-found fame won't distract him from telling his very human stories.

And that's it for today. Thanks for reading. We'll be back at the same time tomorrow morning with the latest.

Thomas and the ABC News Digital team.

Patients have been left frustrated and scared after learning that a life-saving breast cancer and endometriosis drug is to be pulled from shelves in Australia and some other countries.